Evidence map›Paper›PMID 38535077›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Validation and Implementation of OptiView and EnVision FLEX Detection Systems for Immunocytochemical Staining Protocols of the Ten Most Commonly Used Diagnostic Markers in Routine Cytopathological Practice.

Anja Dremelj, Simona Miceska, Anamarija Kuhar, Natasa Nolde, Veronika Kloboves-Prevodnik

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anja DremeljInstitute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.
Simona MiceskaInstitute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.ORCID 0000-0003-1889-1991
Anamarija KuharInstitute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.
Natasa NoldeInstitute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.
Veronika Kloboves-PrevodnikInstitute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.ORCID 0000-0002-0605-6596

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The withdrawal of the iView detection system (iV) forced many cytopathology laboratories, including ours, to substitute immunocytochemical (ICC) staining protocols for routine practice with other detection systems. Our objective was to optimize, validate, and implement ICC protocols using OptiView (OV) and EnVision FLEX (EnV) detection systems, comparing the results with those obtained using iV. Residual cytologic samples with known diagnoses were used, testing antibodies for the ten most common markers in routine cytopathology diagnostics (calretinin, Ber-EP4, MOC-31, CKAE1/AE3, CK5/6, CD68, LCA, desmin, HBME-1, and WT1). Different staining parameters were tested using OV on BenchMark ULTRA and EnV on Dako Omnis immunostainer, respectively. Optimal staining protocols were then selected and validated on 10 positive and 10 negative cases. The staining results were compared with iV protocols through evaluation of UK NEQAS and internal scores. The optimal staining protocols with OV and EnV demonstrated similar or superior results compared to the existing iV protocols, with slightly stronger intensity regarding positive cells. We have successfully established and validated optimal ICC staining protocols for commonly used markers in routine cytopathology practice. These protocols may benefit other laboratories using similar staining platforms. However, the challenge regarding standardizing ICC protocols across different cytopathology laboratories remains unresolved.

Indexed as

BenchMark ULTRA immunostainercytopathologyDako Omnis immunostainerdetection systemsEnVision FLEXimmunocytochemistryiViewOptiViewstaining protocols

Identifiers

PMID38535077
PMCPMC10968775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.